Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Oct 1;177(10):965-973.
doi: 10.1176/appi.ajp.2020.19080844. Epub 2020 Jul 14.

Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study

Laura E Dichtel  1 , Linda L Carpenter  1 , Maren Nyer  1 , David Mischoulon  1 , Allison Kimball  1 , Thilo Deckersbach  1 , Darin D Dougherty  1 , David A Schoenfeld  1 , Lauren Fisher  1 , Cristina Cusin  1 , Christina Dording  1 , Nhi-Ha Trinh  1 , Paola Pedrelli  1 , Albert Yeung  1 , Amy Farabaugh  1 , George I Papakostas  1 , Trina Chang  1 , Benjamin G Shapero  1 , Justin Chen  1 , Paolo Cassano  1 , Emily M Hahn  1 , Elizabeth M Rao  1 , Roscoe O Brady Jr  1 , Ravinder J Singh  1 , Audrey R Tyrka  1 , Lawrence H Price  1 , Maurizio Fava  1 , Karen K Miller  1
Affiliations
Randomized Controlled Trial

Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study

Laura E Dichtel et al. Am J Psychiatry. .

Abstract

Objective: Low-dose testosterone has been shown to improve depression symptom severity, fatigue, and sexual function in small studies in women not formally diagnosed with major depressive disorder. The authors sought to determine whether adjunctive low-dose transdermal testosterone improves depression symptom severity, fatigue, and sexual function in women with antidepressant-resistant major depression. A functional MRI (fMRI) substudy examined effects on activity in the anterior cingulate cortex (ACC), a brain region important in mood regulation.

Methods: The authors conducted an 8-week randomized double-blind placebo-controlled trial of adjunctive testosterone cream in 101 women, ages 21-70, with antidepressant-resistant major depression. The primary outcome measure was depression symptom severity as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary endpoints included fatigue, sexual function, and safety measures. The primary outcome of the fMRI substudy (N=20) was change in ACC activity.

Results: The participants' mean age was 47 years (SD=14) and their mean baseline MADRS score was 26.6 (SD=5.9). Eighty-seven (86%) participants completed 8 weeks of treatment. MADRS scores decreased in both study arms from baseline to week 8 (testosterone arm: from 26.8 [SD=6.3] to 15.3 [SD=9.6]; placebo arm: from 26.3 [SD=5.4] to 14.4 [SD=9.3]), with no significant difference between groups. Improvement in fatigue and sexual function did not differ between groups, nor did side effects. fMRI results showed a relationship between ACC activation and androgen levels before treatment but no difference in ACC activation with testosterone compared with placebo.

Conclusions: Adjunctive transdermal testosterone, although well tolerated, was not more effective than placebo in improving symptoms of depression, fatigue, or sexual dysfunction. Imaging in a subset of participants demonstrated that testosterone did not result in greater activation of the ACC.

Trial registration: ClinicalTrials.gov NCT01783574.

Keywords: Antidepressant-Resistant Depression; Augmentation; Major Depressive Disorder; Placebo Effect; Testosterone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Depression severity over time represented by mean MADRS score (±SD) in the testosterone (solid black circle, solid black line) and placebo (open diamond, dotted line) groups by study visit. There was no significant difference between the testosterone and placebo groups at any visit.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. - PubMed
    1. Celotti F, Melcangi RC, Martini L. The 5 alpha-reductase in the brain: molecular aspects and relation to brain function. Front Neuroendocrinol. 1992;13(2):163–215. - PubMed
    1. Patchev VK, Schroeder J, Goetz F, Rohde W, Patchev AV. Neurotropic action of androgens: principles, mechanisms and novel targets. Exp Gerontol. 2004;39(11–12):1651–1660. - PubMed
    1. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153(8):974–984. - PubMed
    1. Celotti F, Negri-Cesi P, Poletti A. Steroid metabolism in the mammalian brain: 5alpha-reduction and aromatization. Brain research bulletin. 1997;44(4):365–375. - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources